Please provide your email address to receive an email when new articles are posted on . After a hyperkalemia event, mineralocorticoid receptor antagonists were discontinued in up to 46% of patients.

The renin-angiotensin system (RAS) becomes active at low blood pressure and forms angiotensin II, a hormone that causes blood vessels to constrict, causing blood pressure to rise again. The enzyme ...

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

Unique Characteristics of Hypertension in Blacks That Influence BP Responses to Drugs That Block the Renin-Angiotensin Activating System (RAAS) Blockade of the RAAS in Blacks for Cardiovascular and ...

Angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor antagonists have become an important tool for the treatment of hypertension and its cardiovascular complications. Inhibition ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

Renin–angiotensin system (RAS) inhibitors — including angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) — slow the progression of mild or moderate chronic kidney ...

Background. Human immunodeficiency virus (HIV)-infected patients demonstrate increased activation of the reninangiotensin-aldosterone system (RAAS). We evaluated changes in immune markers with ...

In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long ...